Prostate cancer metastasis to bone marrow involves initial adhesion of tumor cells to the bone marrow endothelium, followed by transmigration and proliferation within the marrow. Rapid, specific adhesion of highly metastatic prostate adenocarcinoma cells Prostate cancer mortality is frequently the result of bone metastasis. The preferential homing of circulating prostate tumor cells to bone marrow is thought to involve an initial rapid adhesion to cells of the bone marrow endothelium, followed by transmigration of the endothelium, engagement of specific receptors, and subsequent proliferation within the bone marrow microenvironment. Molecular mechanisms underlying these processes are poorly understood, but there is evidence that tumor cells may exploit existing pathways utilized by circulating blood cell progenitors to gain access to bone marrow.
Prostate cancer mortality is frequently the result of bone metastasis. The preferential homing of circulating prostate tumor cells to bone marrow is thought to involve an initial rapid adhesion to cells of the bone marrow endothelium, followed by transmigration of the endothelium, engagement of specific receptors, and subsequent proliferation within the bone marrow microenvironment. Molecular mechanisms underlying these processes are poorly understood, but there is evidence that tumor cells may exploit existing pathways utilized by circulating blood cell progenitors to gain access to bone marrow.
To identify potential cell adhesion molecules involved in prostate tumor bone metastasis, research in our laboratory has focused on the interaction of prostate carcinoma cells with bone marrow endothelial cells (BMECs). 1 Highly metastatic PC3M-LN4 cells (1) were found to adhere rapidly to human bone marrow-derived sinusoidal endothelial cell lines, whereas poorly metastatic LNCaP cells were only weakly adherent (2) . This adhesion, specific for BMECs relative to other endothelial cells, was subsequently found to depend upon the presence of a pericellular hyaluronan (HA) matrix assembled on the PC3M-LN4 cells. The presence of pericellular HA further correlated with elevated HA synthesis and expression of HA biosynthetic enzymes in the metastatic cells. Collectively, our results may implicate tumor cell-associated HA and up-regulation of HA synthase (HAS) in prostate cancer progression, possibly by facilitating arrest in the bone microvasculature and/or preferential tissue colonization of individual tumor cells.
HA is a ubiquitous polysaccharide component of extracellular and cell-associated matrices (3, 4) , essential for growth and motility of both normal and transformed cells (3, (5) (6) (7) . In some cell types, this requirement entails assembly of a pericellular HA matrix (8, 9) . Cell-associated HA is thought to stimulate cellular detachment during proliferation and migration, and HA deposition is associated with normal and transformed cell growth and migration in several species (10) . Elevated levels of HA in urine and serum often correlate with advanced cancer (11, 12) . Production of HA is thought to be directly involved in prostate cancer progression. In human cancerous prostates, HA levels are increased on the carcinoma cells and correspond to dedifferentiation of the cancer (13, 14) .
HA biosynthesis is catalyzed by transmembrane HAS enzymes (15) . Three human isoforms have been identified and cloned (HAS1 (16) , HAS2 (17) , and HAS3 (18) ). The cDNA of each isoform is capable of conferring HA synthesis and pericellular HA retention to transfected cells. HAS expression is ubiquitous, but isoforms exhibit temporal and tissue-specific distribution. HAS2, for example, is essential for mouse pericardial endothelial cell migration and transformation to mesenchyme during cardiac development (19). HAS2 is also specifically up-regulated in response to wounding in a mesothelial cell model (20) . Overexpression of HAS2 in fibrosarcoma cells or HAS3 in prostate carcinoma cells yields significantly larger subcutaneous tumors in nude mice (21, 22) . Mammary carcinoma cells transfected with HAS1 are more metastatic than control cells (23) . In a melanoma model, tumor cells selected for abundant cell-surface HA were highly tumorigenic and metastatic, whereas tumor cells bearing little or no surface HA, although equally tumorigenic, did not metastasize (6) . In the latter model, however, HAS isoform expression was not characterized. Collectively, these results suggest involvement of HA in tumor growth and metastasis and imply that specific HAS isoforms and/or expression levels of those isoforms may mediate these processes. Expression of HAS appears to correlate directly with HA synthesis (24) , suggesting that elevated HA in tumor cells is probably a reflection of HAS gene expression.
In our previous report, we determined that HAS2 and HAS3, normally present at low levels in the prostate, are strongly up-regulated in metastatic prostate tumor cells (2) . In this report, we have used the in vitro BMEC adhesion model to examine the role of these enzymes and their product in prostate cancer bone metastasis. Specifically, we have manipulated expression of HAS2 and HAS3 in tumor cell lines and evaluated them for HA synthesis, pericellular HA retention, and HA-dependent adhesion to BMECs. Individual inhibition of HAS2 or HAS3 expression in metastatic PC3M-LN4 cells was found to diminish pericellular HA retention and BMEC adhesion; however, complete inhibition of HA-mediated adhesion was obtained by double antisense expression. Conversely, we found that overexpression of either HAS2 or HAS3 in non-metastatic LNCaP cells conferred pericellular HA retention and HA-mediated adhesion to BMECs. These results definitively implicate HAS expression in rapid adhesion of prostate carcinoma cells to BMECs, which may thereby impact the bone metastatic potential of circulating tumor cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents-LNCaP human prostate adenocarcinoma cells were purchased from American Type Culture Collection (Manassas, VA) and cultured in RPMI 1640 medium containing 10% fetal bovine serum. The PC3 derivative cell line PC3M-LN4 (also a human prostate adenocarcinoma cell line) was kindly provided by Dr. Isaiah J. Fidler (M. D. Anderson Hospital Cancer Center, Houston, TX) and was maintained in MEM containing 10% fetal bovine serum, sodium pyruvate, and nonessential amino acids. Prostate carcinoma cells were plated 2 days prior to experiments and used at ϳ70% confluence. Transformed human BMECs (TrHBMECs) were a gift from Dr. Karin Schweitzer (Free University Hospital Amsterdam, Amsterdam, The Netherlands) and were maintained in RPMI 1640 medium containing 10% fetal bovine serum (25) . Aggrecan was prepared as previously described (26) from Swarm rat chondrosarcoma.
Plasmid Construction-Full-length human HAS3 cDNA was subcloned by PCR using oligonucleotides that incorporated flanking SacI and EcoRI restriction sites. HAS2 cDNA was amplified by RT-PCR from PC3M-LN4 mRNA using oligonucleotides that incorporated NheI and BamHI restriction sites. Full-length cDNAs were inserted in pIRES2-EGFP (CLONTECH) via the NheI/BamHI (HAS2) or SacI/EcoRI (HAS3) restriction sites. The sequences were verified and found to be identical to the published sequence. For antisense constructs, HAS2 or HAS3 plasmid DNA was used as the template to amplify the first 300 bases of each isoform sequence, including the ATG start codon, which was then subcloned in the antisense orientation into pIRES-Hyg (CLONTECH). For double antisense HAS inhibition, we expressed antisense HAS2 as a bicistronic message with GFP (pIRES2-EGFP vector) and antisense HAS3 with hygromycin resistance (pIRES-Hyg).
Transfection of Prostate Carcinoma Cells-LNCaP cells were transfected with Lipofectin reagent (Invitrogen) in serum-free medium according to the manufacturer's protocol and allowed to recover in complete standard culture medium for 24 -48 h before assaying. GFP expression was verified in LNCaP cells by flow cytometry, and expression of HAS2 and HAS3 RNAs was ascertained by RT-PCR as described below. PC3M-LN4 cells were incubated for 30 min in serum-free minimal essential medium containing 0.5 units/ml chondroitinase ABC (Sigma) to remove inhibitory glycosaminoglycans and subsequently transfected with FuGENE 6 liposome-mediated transfection reagent (Roche Molecular Biochemicals).
Preparation of Stable Antisense HAS Transfectants-PC3M-LN4 cells were cotransfected with pIRES2-EGFP and pIRES-Hyg for the vector-transfected control, termed GFP. Individual antisense HAS2 or HAS3 transfectants were created by cotransfection of pIRES2-EGFP and HAS2-Hyg or HAS3-Hyg, respectively. Double antisense HAS transfectants received HAS2-GFP and HAS3-Hyg. All transfectants were selected through multiple rounds of fluorescence-activated cell sorting (FACS) and antibiotic selection in 1 mg/ml G418 and 0.8 mg/ml hygromycin until the final cell populations were 85-95% positive for GFP expression. Once established, stable transfectants were maintained in the parental medium supplemented with 1 mg/ml G418 and 0.5 mg/ml hygromycin.
Determination of HAS Expression-HAS isoform and relative level of expression in prostate carcinoma cell lines was semiquantitatively assayed by RT-PCR as previously described (2) . Briefly, poly(A) ϩ RNA was isolated from subconfluent LNCaP and PC3M-LN4 transfectants with the Oligotex mRNA isolation kit (QIAGEN Inc.) and quantitated by Ribogreen fluorescence (Molecular Probes, Inc., Eugene, OR). 20 ng of each mRNA template was reverse-transcribed with an oligo(dT) primer using the Sensiscript kit (QIAGEN Inc.). PCR oligonucleotides specific for HAS2 and HAS3 messages were designed from the sequence data base; expected product sizes are 980 base pairs for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) message, 210 base pairs for HAS2 message, and 410 base pairs for HAS3 message. GAPDH was amplified with each reaction to standardize conditions using oligonucleotides available from Invitrogen. Cycling conditions for HAS2 and HAS3 amplification from PC3M-LN4 cells were optimized independently as follows: 1-min initial denaturation at 95°C; 33 cycles (HAS2) or 25 cycles (HAS3) of 30-s denaturation, 30-s annealing at 60°C, and 30-s polymerization at 72°C; and 5-min final extension at 72°C. For cDNA amplification from LNCaP transient transfectant mRNA, 30 cycles of the above conditions were uniformly employed. A 15-l aliquot of each reaction was electrophoresed on a 3% agarose gel, stained with ethidium bromide, and digitally photographed.
Flow Cytometric Assay for Surface HA Retention-LNCaP transfectants were analyzed in suspension for the retention of cell-surface HA. 2 days post-transfection, cells were released with PBS containing 3 mM EDTA, washed with FACS buffer (PBS containing 1 mM CaCl 2 and 1 mM MgCl 2 ), passed twice through a mesh cell filter to remove aggregates, and resuspended at 5 ϫ 10 5 cells/ml in FACS buffer with or without 16 units/ml Streptomyces hyaluronidase (HAase) (Calbiochem). Cells were incubated at 37°C for 30 min and then washed and resuspended in FACS buffer containing biotinylated HA-binding protein (HABP) (Seikagaku America, Inc.) at a final concentration of 2 g/ml. Following a 90-min room temperature incubation with agitation, cells were washed with FACS buffer, resuspended in streptavidin-conjugated perCP (PharMingen) at a final dilution of 1:200, and incubated for an additional 1 h under the same conditions. After a final wash in FACS buffer, cells were resuspended in 0.3 ml of FACS buffer and immediately analyzed by flow cytometry. Results were gated to include only GFP-fluorescing cells and plotted as a histogram for HABP positivity.
HA Synthesis Quantitation-The concentration of HA in transfected cell culture supernatants was determined in a competitive binding assay (27) . Immulon 96-well microtiter plates were coated with human umbilical cord HA at 50 g/ml in 200 mM carbonate buffer (pH 9.6) overnight at 4°C. Excess HA was removed, and wells were blocked with four washes of Pierce Superblock reagent. Prostate carcinoma cells (30,000 cells/well) were plated overnight in 24-well plates. Cells were washed, given fresh media, and incubated for an additional 20 -24 h. Overnight conditioned culture media were harvested, and cell counts were determined by trypsin release and manual counting in a hemocytometer. Cell culture supernatants were centrifuged to remove cellular material or particulates, boiled for 20 min to inactivate protein components, and serially diluted in PBS and 0.05% Tween 20. Equal volumes of each dilution were combined with biotinylated HABP (Seikagaku America, Inc.) to a final HABP concentration of 1 g/ml and incubated in the HA-precoated wells at room temperature for 6 -8 h. The plate was washed four times with PBS and Tween 20 and developed using an avidin-biotin-horseradish peroxidase system (Vector Laboratories ABC-HRP PK-4000 kit) with tetramethylbenzidine (Sigma) as substrate, and absorbance was read at 650 nm. HA concentration was interpolated from a standard curve of absorbance values corresponding to known HA quantities. The mean HA concentration for each sample of culture supernatant was calculated, and results were normalized to cell num-ber. Data are presented as mass of HA (in micrograms)/10 6 cells. Cell Adhesion Assay-Subconfluent prostate carcinoma cells were PBS/EDTA-released, washed with adhesion medium (RPMI 1640 medium with 0.1% BSA and 20 mM HEPES (pH 7.4), maintained throughout the assay at 37°C), and resuspended at 1 ϫ 10 6 cells/ml in adhesion medium. Cells were incubated with 25 g/ml calcein/AM (Molecular Probes, Inc.; a compound that is converted to a fluorophore only upon uptake and metabolism by living cells) for 20 min, washed with adhesion medium, and resuspended at 1 ϫ 10 5 cells/ml. TrHBMECs were seeded 100% confluent (ϳ40,000 cells/well) in 48-well plates overnight and washed twice with adhesion medium prior to the assay. Prostate carcinoma cells (300 l/well) were added to the confluent endothelial cell monolayers and incubated for 12 min at 37°C unless otherwise indicated. Non-adherent cells were removed with two washes done by gently pipetting 2 ϫ 0.5 ml of adhesion medium and immediately decanting. Viability of non-adherent cells was verified by trypan blue exclusion. Adherent cells were solubilized with PBS containing 0.2 N NaOH and 1% SDS and quantified in a Cytofluor II fluorescence plate reader at 485/530 nm (Biosearch Inc., Bedford, MA).
Inhibition of Cell Adhesion-Calcein/AM-labeled prostate carcinoma cell suspensions (5 ϫ 10 5 cells/ml) were preincubated with 16 units/ml Streptomyces HAase for 25 min and diluted to 1 ϫ 10 5 cells/ml with adhesion medium prior to the assay. HAase was present throughout the assay.
Particle Exclusion Assay-Pericellular HA matrices were visualized as described (8) . Briefly, prostate carcinoma cells cultured overnight in 48-well plates were washed and treated for 25 min at 37°C in the absence or presence of Streptomyces HAase (16 units/ml in phenol red-free MEM with 0.1% BSA). This medium was removed, and cells were incubated for 90 min with 2 mg/ml aggrecan in MEM and 0.1% BSA at 37°C. The aggrecan solution was removed, and 1 ϫ 10 8 glutaraldehyde-fixed sheep red blood cells (Accurate Chemical & Scientific Corp.) in PBS and 1% BSA were added, allowed to settle for 15 min, and then viewed by phase-contrast microscopy. The HA matrix was evidenced by halos surrounding the cells from which the fixed erythrocytes were excluded. Representative cells were photographed at a magnification of ϫ400. To quantify matrix retention, outlines of matrices and cellular boundaries from 10 -15 individual cells of each type were traced, and relative areas were calculated using NIH Image software. HA matrix thickness is presented as the ratio of matrix area to cell area for each transfectant or condition. Values for individual cell tracings were plotted, with mean values represented in each distribution by a horizontal bar. A ratio of 1 indicates complete absence of pericellular clearing.
RESULTS

HAS Overexpression and Antisense Inhibition
Strategy-In our previous work (2), we correlated overexpression of mRNA for HAS2 and HAS3 with aggressive prostate carcinoma cell lines. We reasoned that altered HA synthesis and/or pericellular HA matrix assembly by prostate carcinoma cells could contribute to tumorigenic or metastatic behavior, either by overall HAS expression level or in an isoform-specific fashion. To establish a functional correlation, we decided to overexpress full-length cDNA for HAS2 or HAS3 in LNCaP cells, which synthesize little or no HA, and to inhibit HAS2 or HAS3 expression in PC3M-LN4 cells, which have a thick pericellular HA matrix. We chose the pIRES2-EGFP eukaryotic expression vector, which expresses inserted cDNA as a bicistronic message with GFP, so cells expressing GFP can be separated from untransfected cells by flow cytometry. Expression of GFP therefore requires the transcription of HAS message and provides a useful detection mechanism for transfected cells expressing high levels of that message. This is particularly critical for antisense RNA expression, where it is frequently difficult to verify the presence of antisense message. The vector also provides an antibiotic resistance gene for stable selection.
HAS2 or HAS3 Overexpression in LNCaP Cells Confers Upregulated HA Synthesis and Pericellular HA RetentionLNCaP cells were transiently transfected with vector alone (GFP) or with vector containing cDNA encoding full-length human HAS2 or HAS3. Transfection efficiencies in the population as measured by flow cytometric analysis of GFP expression were consistently 7-10% for HAS2 cDNA and 15-20% for HAS3 cDNA. Expression of HAS mRNA in the transfected cells was verified by RT-PCR (Fig. 1) . Consistent with our previous characterization of the LNCaP cell line (2), GFP control transfectants did not yield detectable amounts of HAS2 product and only small quantities of HAS3 (lanes 4 and 9, respectively). Easily amplified HAS2 and HAS3 products were found only in the respective transfected cell types: lanes 5 and 10 in Fig. 1 correspond to HAS2 transfectants, and lanes 6 and 11 are HAS3 transfectants. Simultaneous control amplification of the GAPDH housekeeping gene from each transfectant is provided in lanes 1-3, and HAS2 (lanes 7 and 8) and HAS3 (lanes 12 and 13) plasmid constructs were amplified as positive controls for specificity of the reactions.
To evaluate functionality of the expressed HAS2 and HAS3 proteins, HA synthesis was measured. It has been shown previously that the majority of HA synthesized by cells in culture is secreted to the culture medium (17) . We analyzed HA secretion by LNCaP transient transfectants in a competitive enzyme-linked immunosorbent assay-like assay as described under "Experimental Procedures." LNCaP GFP transfectant culture supernatants were found to contain Ϸ0.5 g of HA/10 6 cells ( Fig. 2) , in close agreement with levels detected in untransfected LNCaP cultures. Following transfection with HAS2 and HAS3 constructs, culture media contained nearly 3-and 4-fold increased HA levels, respectively, confirming enzymatic activity of the transfected cDNA products. Remarkably, the quantity of HA detected in HAS-transfected supernatants was greater by 1-1.5 g/10 6 cells than in controls. Normalized to the 10 -15% transfection efficiency of the cells, this HA increase corresponds to a synthesis rate of Ϸ10 -15 g/10 6 transfected cells, which is on the order of catalysis measured for the PC3M-LN4 cell line (see Fig. 7 ).
To assess potential cell-surface HA retention resulting from enhanced HA production, we used particle exclusion. In this assay, cells were preincubated with a specific HA-binding proteoglycan (aggrecan), and small red blood cells were allowed to settle around the much larger prostate cells. Those cells with surface-associated HA exhibited surrounding clear zones. Both the HAS2-and HAS3-transfected LNCaP cells were clearly observed to have a halo (Fig. 3, B and C, respectively) , whereas the GFP control (Fig. 3A) lacked such a pericellular zone of exclusion, indicating that transfection of LNCaP cells with HAS2 or HAS3 also conferred surface HA retention. Cells did not appear to exhibit any isoform specificity with regard to the thickness of the matrix as measured in this assay. However, there was a definite correlation between intensity of GFP fluorescence (indicative of transfected cells) and matrix size (data not shown). To verify the HA content of the matrices produced by HAS-transfected cells, transfectants were digested with HAase prior to addition of aggrecan, upon which the pericellular clear zones were no longer visible (Fig. 3, D-F) . ϩ RNA was isolated from each transfectant, reverse-transcribed, and amplified by PCR with primers specific for GAPDH (980 bp; lanes 1-3), HAS2 (210 bp; lanes 4 -8) , and HAS3 (410 bp; lanes 9 -13) . Lanes 1, 4 , and 9 correspond to GFP control transfectants. Lanes 2, 5, and 10 contain products amplified from HAS2-transfected cells. Lanes 3, 6, and 11 are from HAS3 transfectants. Lanes 7 and 12 (HAS2) and lanes 8 and 13 (HAS3) are plasmid DNA controls.
HAS2-or HAS3-transfected LNCaP Cells
Retain Cell-associated HA in Suspension-To verify retention of cell-associated HA in suspended cells, we performed a two-color FACS analysis. Single cell suspensions of LNCaP cells transiently transfected with GFP control, HAS2, or HAS3 constructs were incubated with a biotinylated HABP probe, detected with a streptavidin-conjugated fluorophore, and analyzed by flow cytometry. Cells were gated to include only GFP-positive transfectants and plotted to illustrate HA binding (Fig. 4, solid line) . HAase sensitivity of the HABP probe demonstrated the specificity of its reactivity with HA and affirmed the HA content of the matrix retained by LNCaP HAS2 and HAS3 transfectants in suspension (dotted line). Using this assay, it was apparent that although both HAS transfectants possessed surface HA, LNCaP HAS3 transfectants (Fig. 4B) , relative to HAS2-transfected cells (Fig. 4A) , retained considerably more matrix with HABP-binding potential composed of HAase-sensitive material. Gating on very high GFP-expressing cells, which would be assumed to represent the highest HAS-expressing population, increased the amount of HABP signal intensity in HAS2 transfectants, but not to the level of HAS3 transfectants (data not shown). Reduced apparent transfection efficiency of HAS2 rendered it difficult to obtain significant numbers of highly GFPpositive cells to analyze, however; so this difference may reflect greater transfected message instability rather than inherent isoform-specific matrix formation.
LNCaP HAS2 and HAS3 Transfectants Adhere to BMECsTo determine whether surface HA retention could mediate adhesion to BMECs, LNCaP HAS2 and HAS3 transfectants and corresponding GFP controls were labeled and applied to confluent TrHBMEC monolayers. Like the parental LNCaP cells, adhesion of GFP control transfectants (Fig. 5, black bars) was very low and unaffected by HAase digestion (white bars). Greater numbers of LNCaP cells transiently transfected with HAS2 (Ϸ8% more, p ϭ 0.068 relative to GFP control) and HAS3 (Ϸ12% more, p Ͻ 0.01 relative to GFP control) were found to adhere to BMECs, and the enhanced adhesion was entirely HAase-sensitive. These increases, although modest, are in close relation to the respective transfection efficiencies of HAS2 and HAS3 constructs. Furthermore, flow cytometric analysis of non-adherent cells relative to total input cells demonstrated removal of GFP-positive cells from the HAS2-and HAS3-transfected populations (data not shown), implying that all transfected cells were adherent. This result is consistent with a direct role for up-regulated HA synthesis and surface HA retention in prostate tumor cell adhesion to BMECs. Furthermore, overexpression of either the HAS2 or HAS3 isoform alone was sufficient to confer these properties to LNCaP cells. 
Antisense HAS Expression Diminishes PC3M-LN4 Synthesis
and Secretion of HA-To evaluate the effect of antisense HAS mRNA expression on prostate tumor cell behavior, we developed four stably transfected PC3M-LN4 cell lines: GFP, bearing the appropriate vector controls; H2as, expressing only antisense HAS2; H3as, with antisense HAS3 only; and H2/3as, a "double knockout" incorporating both antisense HAS2 and HAS3. We have previously used semiquantitative RT-PCR to demonstrate that PC3M-LN4 cells express relatively high levels of HAS2 and HAS3 mRNAs. By the same methodology, equal amounts of poly(A) ϩ RNA from each of the four stably transfected cell lines were analyzed by RT-PCR for HAS2 (Fig.  6, upper panel, lanes 5-10) and HAS3 (lower panel, lanes 5-10) expression. GAPDH was simultaneously amplified with each set of reactions to control for input RNA (lanes 1-4) . Fig. 6  (upper panel, lanes 6 and 8) shows reduced HAS2 message in H2as and H2/3as transfectants, respectively, whereas GFP control and H3as transfectants retained comparable expression (lanes 5 and 7) . HAS3 expression, unaffected in GFP control or H2as transfectants (lower panel, lanes 5 and 6), was significantly diminished in both H3as and H2/3as cells (lanes 7 and  8) . These results demonstrate efficacy and isoform specificity of antisense HAS inhibition, although endogenous HAS gene expression appeared to be incompletely suppressed.
We next used a competitive binding assay to quantify HA synthesis and secretion by each cell line and to evaluate potential functional differences. As shown in Fig. 7 , GFP controls produced Ϸ13 g of HA/10 6 cells in 20 h, consistent with our previous results for untransfected PC3M-LN4 cells. H2as transfectants produced about half as much HA as the control cells (Ϸ7 g/10 6 cells), reflecting the significantly diminished HAS2 expression observed by RT-PCR. H3as transfectants secreted Ϸ5 g of HA/10 6 cells in 20 h, and the H2/3as cell supernatants contained Ͻ4 g of HA/10 6 cells. These results show dramatic inhibition of HA synthesis by stable transfection with antisense HAS and possibly suggest that HAS3 may produce more of the cellular HA than HAS2, although it is clear that there is residual HAS expression even in the presence of both antisense messages.
Antisense HAS Expression in PC3M-LN4 Cells Reduces Matrix Thickness-We next evaluated the antisense PC3M-LN4 cell lines by particle exclusion to determine whether antisense HAS transfection affected cell-surface HA retention. The vector control transfectants retained HAase-sensitive matrices (Fig.  8A and inset) of comparable thickness to the parental PC3M-LN4 cells (Fig. 8E) . Antisense HAS2 or HAS3 transfectants (Fig. 8, B and C) , although still surrounded by pericellular HA, appeared to have matrices of diminished thickness. H2/3as cells (Fig. 8D) did not appear to retain HA at the cell surface (compare with 8A, inset, HAase-treated). To quantify matrix thickness, outlines of matrices and cellular boundaries from 10 individual cells were traced, and relative areas were calculated using NIH Image software. Coat thickness was plotted as the ratio of matrix area to cell area (coat/cell area ratio) for each transfectant as well as for the parental PC3M-LN4 cell line with and without HAase treatment (Fig. 8E) . The mean ratio for each condition is indicated by a horizontal bar. The parental cell line bore a very thick coat, with coat/cell area ratios averaging 2.6. HAase treatment reduced this ratio to ϳ1.3, demonstrating virtually complete removal of HA from the cell surface (a ratio of 1 signifies absence of matrix). GFP vector control transfectants had comparable coat/cell area ratios relative to parental cells, but these ratios were significantly reduced in single antisense HAS2 and HAS3 transfectants (Ϸ2 and 1.5, respectively) as well as in the H2/3as cell line (Ϸ1.3). These quantitations correlated well with trends observed in HA synthesis by the respective cells and suggest a direct correlation among HAS expression, HA synthesis levels, and pericellular matrix retention. 1 and 5) , vector encoding bicistronic antisense HAS2-GFP (lanes 2 and 6), vector encoding bicistronic antisense HAS3-GFP (lanes 3 and  7) , or vector encoding double antisense HAS2/HAS3 (lanes 4 and 8) as described under "Experimental Procedures." Poly(A) ϩ RNA was isolated from each transfectant, reverse-transcribed, and amplified by PCR with primers specific for GAPDH (980 bp; lanes 1-4) , HAS2 (210 bp; upper panel, lanes [5] [6] [7] [8] [9] [10] , and HAS3 (410 bp; lower panel, lanes [5] [6] [7] [8] [9] [10] . Plasmids containing full-length HAS2 and HAS3 cDNAs (lanes 9 and 10, respectively) were amplified concurrently as controls.
FIG. 7.
Inhibition of HAS2 and/or HAS3 expression in PC3M-LN4 cells by stable antisense transfection reduces HA synthesis and secretion. PC3M-LN4 cells were selected as described under "Experimental Procedures" for stable expression of control vectors alone (GFP) or vectors encoding antisense HAS2 RNA (H2as), antisense HAS3 RNA (H2as), or double antisense HAS2/HAS3 RNA (H2/3as). Transfectants were seeded in triplicate wells of a 24-well plate (30,000 cells/well). Seeding media were removed the following day; cells were washed; and fresh medium was applied. These overnight conditioned media were then harvested and analyzed for HA content by competitive binding assay as described under "Experimental Procedures." HA quantity was normalized to cell number as determined by trypsin release and manual counting in a hemocytometer. Data are presented as the means Ϯ S.E. of three independent HA quantitations performed on triplicate culture supernatants for each transfectant.
Antisense Expression Inhibits BMEC Adhesion-To examine the role of HA synthesis and surface retention in PC3M-LN4 intercellular interaction with BMECs, we performed adhesion assays as described under "Experimental Procedures." Inhibition of HAS2 or HAS3 expression individually was observed to diminish adhesion of PC3M-LN4 cells to TrHBMECs (Fig. 9) . Adhesion was further inhibited by digestion with HAase, however, suggesting that there is sufficient residual synthesis of HA by the remaining HAS isoform in either the single antisense HAS2 or HAS3 transfectants to promote BMEC adhesion. The greatest inhibition was observed in antisense HAS3, which may imply that although HAS2 is active and sufficient to maintain HA synthesis required for BMEC adhesion, HAS3 actually is more critical to the process than HAS2. The level of adhesion following HAase digestion of HAS3 transfectants was also decreased relative to controls (ϳ25% adhesion relative to 45% for vector controls), suggesting that HA-mediated adhesion may be a more significant percentage than is apparent from digestion of parental cells. HA was probably re-synthesized on the time scale of the assay in the parental and vector control cells, whereas antisense HAS slowed the rate of surface matrix replenishment, thus decreasing adhesion to BMECs. This is further supported by the effect of double antisense H2/3as inhibition: adhesion of these transfectants to BMECs was reduced below the level of HAase-inhibited control cell adhesion, and there was a virtual absence of HAase sensitivity. HAase treatment of these cells did not reduce adhesion below levels following HAase digestion of H3as cells, again strongly implying that HAS3 may synthesize most of the overproduced HA required to promote adhesion of PC3M-LN4 cells to BMECs.
DISCUSSION
Prostate cancer bone metastasis is the most frequent cause of mortality in patients with prostate cancer. The origin of preferential bone metastasis by prostate tumor cells may therefore reside in expression of a unique and complementary profile of adhesion molecules and receptors by prostate and bone marrow endothelial cells that would facilitate the arrest of circulating cells in the bone marrow microvasculature. In this report, we have demonstrated the role of two specific genes in modulation of rapid adhesion by prostate tumor cells in suspension to cultured BMEC monolayers. The overproduction of HA induced by transfection of LNCaP cells with HA biosynthetic enzyme isoforms HAS2 and HAS3 was sufficient to enhance HA-mediated adhesion of these cells to TrHBMECs. Conversely, decreased HA production by antisense HAS2 and HAS3 expression in PC3M-LN4 cells eliminated the pericellular HA matrix normally retained by these cells and abolished HA-mediated adhesion to TrHBMECs. Up-regulation of HA biosynthetic enzymes may therefore be one mechanism governing preferential bone metastasis.
Individual HAS isoform expression in LNCaP cells is sufficient for elevated HA synthesis, leading to surface HA retention, which mediates BMEC adhesion. It is worth noting that LNCaP cells do not express CD44, the primary cell-surface receptor for HA (28) , shown many times in other studies to be a requisite component of HA matrices. This argues that other HA receptors must be cross-linking HA into a matrix or that HAS enzymes themselves, when present at high levels in the cell membrane, retain considerable amounts of HA. The presence of HA alone is capable of promoting intercellular adhesion: as a result of its repetitive polymeric structure, it exhibits multivalent binding characteristics, simultaneously ligating receptors on multiple cells. In our studies with LNCaP cells, it was difficult to distinguish the relative effects of the two HAS isoforms. Although it appeared that HAS2 was less active in HA overproduction and surface retention, when normalized to transfection efficiency, both enzymes catalyzed sufficient HA synthesis to mediate equivalent BMEC adhesion, suggesting similarity of the products with regard to ligation of adhesion molecules and/or receptor engagement.
HAS overexpression has been correlated with aggressive cell behaviors in several other model systems. Treatment of mesothelial cells with several pro-inflammatory cytokines (24) increases HAS2 expression, and manual wounding of cultured peritoneal mesothelial cells specifically induces HAS2 up-regulation at the wounded edge of the monolayer (20) . HAS2 clearly appears to have a role in wound healing and inflammation and also appears to be the most highly regulated isoform because these studies reported no significant changes in the levels of HAS1 or HAS3 transcripts. Overexpression of HAS1 in a syngeneic mouse mammary carcinoma model resulted in increased lung metastasis following intravenous injection (23) . Although human breast cancers also metastasize preferentially to bone marrow, bone metastasis was not addressed in that model. HAS2 overexpression has been shown to promote anchorage-independent growth in HT1080 fibrosarcoma cells (21) and malignant mesotheliomas (29) as well as to increase migration (29) and to enhance subcutaneous tumorigenicity in nude mice (21) . HAS3 overexpression in TSU prostate carcinoma cells (22) yields bigger subcutaneous tumors in nude mice, but has no effect on lung metastasis following intravenous injection. HAS enzymes therefore also function to promote growth and motility; however, no studies have addressed the effect of HAS expression on bone metastatic proclivity.
Fewer studies documenting inhibition of HA synthesis have been published. The most conspicuous HAS inhibitors reported to date include hydrocortisone (24) , which suppresses HAS2 expression in mesothelial cells almost entirely, and dexamethasone, another glucocorticoid that rapidly down-regulates HAS2 expression in skin fibroblasts (30) . The former study again reported no effect on HAS1 or HAS3 message levels, suggesting that HAS2 may be the most transiently regulated of the three genes. Our characterization of prostate carcinoma cell lines by RT-PCR demonstrated elevated expression of both HAS2 and HAS3 relative to normal prostate epithelial cells, with overexpression of HAS3 correlating most closely to the reported metastatic potential of the cell lines. Because HAS3 appears to be less regulated at the transcriptional level, the consequences of its basal overexpression by tumor cells are likely to be dramatic and difficult to alleviate.
To directly ascertain the impact of HAS expression on HA matrix retention and adhesion to BMECs, we employed a 2-fold strategy: up-regulation in cells lacking HA (LNCaP) and inhibition of HAS gene expression in cells with a thick pericellular HA matrix (PC3M-LN4). The latter strategy required stable selection for antisense HAS expression to obtain a significant decrease in HA secretion, reflecting the difficulty of achieving complete knockout. Inhibition of individual HAS isoforms, although able to decrease HA production, matrix retention, and adhesion to BMECs, did not completely abolish these functions, suggesting that each isoform alone actively produces HA in PC3M-LN4 cells. HA production and BMEC adhesion were more significantly reduced in HAS3-inhibited cells, which could be indicative of more efficient HAS3 enzyme catalysis. Kinetic characterizations of HAS in reconstituted liposomes showed equivalent catalytic rates for HAS2 and HAS3 (31), however. Rather, this observation is consistent with greater detectable expression of HAS3 relative to HAS2 (2) and with a potential correlation between adhesive/metastatic potential and levels of HAS3. Because adhesion of double antisense HAS-inhibited tumor cells was almost entirely reduced to a basal percentage, we conclude that surface HA retention is both necessary and sufficient for rapid maximal intercellular adhesion in our cell culture model.
Histopathologic studies of human prostate cancer have shown that HA levels increase in tumors as a function of increasing pathologic grade (13, 14) . These data suggest that tumor cells may develop an enhanced capacity to synthesize and retain pericellular HA. Consequently, the cells become surrounded by a hydrated envelope that facilitates invasiveness, perhaps by altering the composition and interfering with the integrity of tissue stromal matrices. This envelope could also permit the tumor cells to evade immune system detection, to adhere to specialized endothelia, and/or to grow in remote sites. Short HA oligosaccharide degradation products have been shown to stimulate angiogenesis (32) , and levels may be elevated in the environs of such tumor cells through the action of HAase enzymes (33) . Inhibition of HAS enzyme expression within the tumor would then be predicted to decrease angiogenesis and thereby suppress tumor growth. HAS expression has not yet been characterized in human tumor tissue.
Tumor cells may utilize adhesive mechanisms for homing to bone marrow that normally occur for the purpose of regulating homing of hematopoietic progenitor cells. Studies of circulating progenitors have demonstrated the involvement of carbohydrate/lectin interactions as well as intercellular adhesion molecules, VCAM, and integrins. In a metastatic myeloma model (34), CD44/HA was required for transmigration of BMEC monolayers. Furthermore, HA binding to CD44 has also been shown to mediate lymphocyte rolling under shear flow conditions (35) . Endothelial adhesion receptor profiles may drive preferential metastasis. Cultured endothelial cells from microvascular versus large vein or arterial sources have been shown to bind significantly greater amounts of HA (36) , which was attributable to differential expression of the HA receptors CD44 and RHAMM (receptor for HA-mediated motility). Ligation of these receptors has been shown to transduce motility signals (37, 38) , perhaps consequently permitting ingress of tumor cells to bone marrow.
The most simple consequence of our results is that tumor cell-associated HA would recognize bone marrow endothelial receptors and arrest the circulating cell in the microvasculature. However, it is possible that this interaction could occur indirectly or be facilitated by indirect interaction with lymphocytes or other CD44-expressing cells in the bloodstream. The presence of such cells in tumor cell aggregates could provide a source of "normal" cross-talk between the tumor cells and the endothelium. Chemokines and their receptors, for example, are required for transendothelial migration of hematopoietic progenitor cells in vitro (39) . Secretion of chemokines or expression of chemokine receptors within the cell aggregates and recognition by the endothelial cognate receptor or ligand would be one mechanism by which transmigration of a tumor cell could be indirectly orchestrated.
We have demonstrated, by manipulation of gene expression, that up-regulated HAS enzymes in prostate tumor cells are responsible for promoting rapid adhesion to BMECs in vitro. This is a novel interaction that has not been previously de-scribed for prostate carcinoma cells. It will be important to determine whether this adhesive preference in vitro translates to preferential arrest and/or homing to the bone marrow microvasculature in a mouse model. We are currently investigating this question. We anticipate that inhibition of HA synthesis by prostate tumor cells or antagonism of HA-mediated adhesion may provide a means of regulating metastatic growth of prostate cancer.
